CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −9,896 | $191.55 | $1.9M | 2,330,576 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −8,579 | $192.79 | $1.7M | 2,321,997 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −7,043 | $193.58 | $1.4M | 2,314,954 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,082 | $194.57 | $794K | 2,310,872 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −100 | $195.32 | $20K | 2,310,772 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise · Stock Option (right to buy) 10b5-1 | −75,000 | 225,000 | ||
| 2026-03-10 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −707 | $204.13 | $144K | 189,199 |
| 2026-03-10 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −915 | $204.13 | $187K | 150,882 |
| 2026-03-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −1,745 | $204.13 | $356K | 233,285 |
| 2026-03-10 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −5,623 | $204.13 | $1.1M | 156,607 |
| 2026-03-10 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −785 | $204.13 | $160K | 63,354 |
| 2026-03-10 | Sheena Jonathan Director | Sale 10b5-1 | −127 | $204.13 | $26K | 262,325 |
| 2026-03-09 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Grant or award 10b5-1 | +1,774 | 189,906 | ||
| 2026-03-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Grant or award 10b5-1 | +1,774 | 151,797 | ||
| 2026-03-09 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Grant or award 10b5-1 | +1,745 | 235,030 | ||
| 2026-03-09 | Chapman Steven Leonard CEO AND PRESIDENT | Grant or award 10b5-1 | +5,623 | 162,230 | ||
| 2026-03-09 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Grant or award 10b5-1 | +1,968 | 64,139 | ||
| 2026-03-09 | Sheena Jonathan Director | Grant or award 10b5-1 | +258 | 262,452 | ||
| 2026-03-06 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Option exercise 10b5-1 | +5,598 | $19.68 | $110K | 241,683 |
| 2026-03-06 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −400 | $193.73 | $77K | 241,283 |
Page 24 of 39 · 767 trades